P.C. Enzinger, and R.J. Mayer Esophageal cancer N Engl J Med 349 2003 2241 2252
B. Kumbasar Carcinoma of esophagus: radiologic diagnosis and staging Eur J Radiol 42 2002 170 180
Y.C. Yoon, K.S. Lee, Y.M. Shim, B.T. Kim, K. Kim, and T.S. Kim Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study Radiology 227 2003 764 770
J.D. Luketich, D.M. Friedman, T.L. Weigel, M.A. Meehan, R.J. Keenan, and D.W. Townsend Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans Ann Thorac Surg 68 1999 1133 1136 discussion: 1136-7
H. Kato, H. Kuwano, M. Nakajima, T. Miyazaki, M. Yoshikawa, and H. Ojima Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma Cancer 94 2002 921 928
T. Lerut, P. Flamen, N. Ectors, E. Van Cutsem, M. Peeters, and M. Hiele Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy Ann Surg 232 2000 743 752
A.C. Kole, J.T. Plukker, O.E. Nieweg, and W. Vaalburg Positron emission tomography for staging of oesophageal and gastroesophageal malignancy Br J Cancer 78 1998 521 527
F.L. Flanagan, F. Dehdashti, B.A. Siegel, D.D. Trask, S.R. Sundaresan, and G.A. Patterson Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography AJR Am J Roentgenol 168 1997 417 424
P. Flamen, A. Lerut, E. Van Cutsem, W. De Wever, M. Peeters, and S. Stroobants Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [see comments] J Clin Oncol 18 2000 3202 3210
M.I. Block, G.A. Patterson, R.S. Sundaresan, M.S. Bailey, F.L. Flanagan, and F. Dehdashti Improvement in staging of esophageal cancer with the addition of positron emission tomography Ann Thorac Surg 64 1997 770 776 discussion: 776-7
K. Kim, S.J. Park, B.T. Kim, K.S. Lee, and Y.M. Shim Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography Ann Thorac Surg 71 2001 290 294
R. Hustinx, R.J. Dolin, F. Benard, A. Bhatnagar, D. Chakraborty, and R.J. Smith Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis Eur J Nucl Med 27 2000 1365 1371
M.B. Wallace, P.J. Nietert, C. Earle, M.J. Krasna, R.H. Hawes, and B.J. Hoffman An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy Ann Thorac Surg 74 2002 1026 1032
J.I. Geh The use of chemoradiotherapy in oesophageal cancer Eur J Cancer 38 2002 300 313
B.L. Brucher, W. Weber, M. Bauer, U. Fink, N. Avril, and H.J. Stein Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography Ann Surg 233 2001 300 309
R.J. Downey, T. Akhurst, D. Ilson, R. Ginsberg, M.S. Bains, and M. Gonen Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial J Clin Oncol 21 2003 428 432
P. Flamen, E. Van Cutsem, A. Lerut, J.P. Cambier, K. Haustermans, and G. Bormans Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann Oncol 13 2002 361 368
H. Kato, H. Kuwano, M. Nakajima, T. Miyazaki, M. Yoshikawa, and N. Masuda Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer Am J Surg 184 2002 279 283
R. Nakamura, T. Obara, S. Katsuragawa, Y. Tamakawa, K. Koeda, and K. Ikeda Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy Radiat Med 20 2002 181 186
N. Arslan, T.R. Miller, F. Dehdashti, R.J. Battafarano, and B.A. Siegel Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer Mol Imaging Biol 4 2002 301 310
G.W. Couper, D. McAteer, F. Wallis, M. Norton, A. Welch, and M. Nicolson Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer Br J Surg 85 1998 1403 1406
W.A. Weber, K. Ott, K. Becker, H.J. Dittler, H. Helmberger, and N.E. Avril Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
H.W. Yeung, H.A. Macapinlac, M. Mazumdar, M. Bains, R.D. Finn, and S.M. Larson FDG-PET in esophageal cancer: incremental value over computed tomography Clin Positron Imaging 2 1999 255 260
P. Flamen, A. Lerut, E. Van Cutsem, J.P. Cambier, A. Maes, and W. De Wever The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J Thorac Cardiovasc Surg 120 2000 1085 1092
D.M. Parkin, P. Pisani, and J. Ferlay Estimates of the worldwide incidence of 25 major cancers in 1990 Int J Cancer 80 1999 827 841
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, and T. Ido Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer J Nucl Med 44 2003 690 699
A. Stahl, K. Ott, W.A. Weber, K. Becker, T. Link, and J.R. Siewert FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 2003 288 295
K. Ott, U. Fink, K. Becker, A. Stahl, H.J. Dittler, and R. Busch Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 2003 4604 4610
E. Mochiki, H. Kuwano, H. Katoh, T. Asao, N. Oriuchi, and K. Endo Evaluation of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer World J Surg 28 2004 247 253
A. Turlakow, H.W. Yeung, A.S. Salmon, H.A. Macapinlac, and S.M. Larson Peritoneal carcinomatosis: role of (18)F-FDG PET J Nucl Med 44 2003 1407 1412
T. De Potter, P. Flamen, E. Van Cutsem, F. Penninckx, L. Filez, and G. Bormans Whole-body PET with FDG for the diagnosis of recurrent gastric cancer Eur J Nucl Med Mol Imaging 29 2002 525 529
H. Jadvar, R. Tatlidil, A.A. Garcia, and P.S. Conti Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography Clin Radiol 58 2003 215 221
S. McKenna, and M. Eatock The medical management of pancreatic cancer: a review Oncologist 8 2003 149 160
R. Bares, P. Klever, S. Hauptmann, D. Hellwig, J. Fass, and U. Cremerius F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer Radiology 192 1994 79 86
T. Inokuma, N. Tamaki, T. Torizuka, Y. Magata, M. Fujii, and Y. Yonekura Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US Radiology 195 1995 345 352
T. Kato, H. Fukatsu, K. Ito, M. Tadokoro, T. Ota, and M. Ikeda Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem Eur J Nucl Med 22 1995 32 39
H. Friess, J. Langhans, M. Ebert, H.G. Beger, J. Stollfuss, and S.N. Reske Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography [published erratum appears in Gut 1995;37:448] Gut 36 1995 771 777
J.C. Stollfuss, G. Glatting, H. Friess, F. Kocher, H.G. Berger, and S.N. Reske 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments] Radiology 195 1995 339 344
M. Zimny, R. Bares, J. Fass, G. Adam, U. Cremerius, and B. Dohmen Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases Eur J Nucl Med 24 1997 678 682
T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, K. Fujimoto, and R. Doi Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET): usefulness and limitations in “clinical reality Ann Nucl Med 17 2003 261 279
D. Delbeke, D.M. Rose, W.C. Chapman, C.W. Pinson, J.K. Wright, and R.D. Beauchamp Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma J Nucl Med 40 1999 1784 1791
A. Imdahl, E. Nitzsche, F. Krautmann, S. Hogerle, S. Boos, and A. Einert Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer Br J Surg 86 1999 194 199
C.G. Diederichs, L. Staib, J. Vogel, B. Glasbrenner, G. Glatting, and H.J. Brambs Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses Pancreas 20 2000 109 116
A. Sendler, N. Avril, H. Helmberger, J. Stollfuss, W. Weber, and F. Bengel Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations World J Surg 24 2000 1121 1129
M. Papos, T. Takacs, L. Tron, G. Farkas, E. Ambrus, and S, Szakall Jr The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions Clin Nucl Med 27 2002 197 201
K. Koyama, T. Okamura, J. Kawabe, B. Nakata, K.H. Chung, and H. Ochi Diagnostic usefulness of FDG PET for pancreatic mass lesions Ann Nucl Med 15 2001 217 224
Y. Nakamoto, T. Higashi, H. Sakahara, N. Tamaki, M. Kogire, and R. Doi Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas Cancer 89 2000 2547 2554
R.K. Kasperk, K.P. Riesener, K. Wilms, and V. Schumpelick Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view World J Surg 25 2001 1134 1139
D.M. Rose, D. Delbeke, R.D. Beauchamp, W.C. Chapman, M.P. Sandler, and K.W. Sharp 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 1999 729 737 discussion: 737-8
P.D. Shreve Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease [see comments] Eur J Nucl Med 25 1998 259 264
M.K. Kalra, M.M. Maher, G.W. Boland, S. Saini, and A.J. Fischman Correlation of positron emission tomography and CT in evaluating pancreatic tumors: technical and clinical implications AJR Am J Roentgenol 181 2003 387 393
M.K. Kalra, M.M. Maher, P.R. Mueller, and S. Saini State-of-the-art imaging of pancreatic neoplasms Br J Radiol 76 2003 857 865
T. Inokuma, N. Tamaki, T. Torizuka, T. Fujita, Y. Magata, and Y. Yonekura Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer J Nucl Med 36 1995 229 235
C.G. Diederichs, L. Staib, G. Glatting, H.G. Beger, and S.N. Reske FDG PET:elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies J Nucl Med 39 1998 1030 1033
C. Sperti, C. Pasquali, F. Chierichetti, G. Liessi, G. Ferlin, and S. Pedrazzoli Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas Ann Surg 234 2001 675 680
T. Belhocine, J. Foidart, P. Rigo, F. Najjar, A. Thiry, and P. Quatresooz Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67 Nucl Med Commun 23 2002 727 734
A. Frohlich, C.G. Diederichs, L. Staib, J. Vogel, H.G. Beger, and S.N. Reske Detection of liver metastases from pancreatic cancer using FDG PET J Nucl Med 40 1999 250 255
Y. Nakamoto, T. Higashi, H. Sakahara, N. Tamaki, M. Kogire, and M. Imamura Contribution of PET in the detection of liver metastases from pancreatic tumours Clin Radiol 54 1999 248 252
K. Kinkel, Y. Lu, M. Both, R.S. Warren, and R.F. Thoeni Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis Radiology 224 2002 748 756
R. Valinas, A. Barrier, F. Montravers, S. Houry, J.N. Talbot, and M. Huguier 18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors Gastroenterol Clin Biol 26 2002 888 892
H.R. Mertz, P. Sechopoulos, D. Delbeke, and S.D. Leach EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma Gastrointest Endosc 52 2000 367 371
B. Nakata, Y.S. Chung, S. Nishimura, T. Nishihara, Y. Sakurai, and T. Sawada 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma Cancer 79 1997 695 699
M. Zimny, J. Fass, R. Bares, U. Cremerius, O. Sabri, and P. Buechin Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma Scand J Gastroenterol 35 2000 883 888
C. Sperti, C. Pasquali, F. Chierichetti, A. Ferronato, G. Decet, and S. Pedrazzoli 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma J Gastrointest Surg 7 2003 953 959 discussion: 959-60
T. Higashi, H. Sakahara, T. Torizuka, Y. Nakamoto, S. Kanamori, and M. Hiraoka Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET J Nucl Med 40 1999 1424 1433
N.R. Maisey, A. Webb, G.D. Flux, A. Padhani, D.C. Cunningham, and R.J. Ott FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study Br J Cancer 83 2000 287 293
C. Franke, R. Klapdor, K. Meyerhoff, and M. Schauman 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma Anticancer Res 19 1999 2437 2442
A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
J. Kievit Follow-up of patients with colorectal cancer: numbers needed to test and treat Eur J Cancer 38 2002 986 999
W.E. Longo, and F.E. Johnson The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer Surg Clin North Am 82 2002 1091 1108
J.A. Meyerhardt, and R.J. Mayer Follow-up strategies after curative resection of colorectal cancer Semin Oncol 30 2003 349 360
B. Ohlsson, and B. Palsson Follow-up after colorectal cancer surgery Acta Oncol 42 2003 816 826
Y.K. Chen, C.H. Kao, A.C. Liao, Y.Y. Shen, and C.T. Su Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan Anticancer Res 23 2003 4357 4361
J.P. Drenth, F.M. Nagengast, and W.J. Oyen Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings Eur J Nucl Med 28 2001 1766 1769
I. Kantorova, L. Lipska, O. Belohlavek, V. Visokai, M. Trubac, and M. Schneiderova Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making J Nucl Med 44 2003 1784 1788
H. Abdel-Nabi, R.J. Doerr, D.M. Lamonica, V.R. Cronin, P.J. Galantowicz, and G.M. Carbone Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings Radiology 206 1998 755 760
R.H. Huebner, K.C. Park, J.E. Shepherd, J. Schwimmer, J. Czernin, and M.E. Phelps A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer J Nucl Med 41 2000 1177 1189
K. Johnson, A. Bakhsh, D. Young, T.E. Martin Jr, and M. Arnold Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer Dis Colon Rectum 44 2001 354 357
M.H. Whiteford, H.M. Whiteford, L.F. Yee, O.A. Ogunbiyi, F. Dehdashti, and B.A. Siegel Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum Dis Colon Rectum 43 2000 759 767 discussion: 767-70
E.E. Zervos, B.D. Badgwell, W.E. Burak Jr, M.W. Arnold, and E.W. Martin Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup Surgery 130 2001 636 643 discussion: 643-4
M. Lonneux, A.M. Reffad, R. Detry, A. Kartheuser, J.F. Gigot, and S. Pauwels FDG-PET improves the staging and selection of patients with recurrent colorectal cancer Eur J Nucl Med Mol Imaging 29 2002 915 921
K.R. Hine, and P.W. Dykes Serum CEA testing in the post-operative surveillance of colorectal carcinoma Br J Cancer 49 1984 689 693
F.L. Flanagan, F. Dehdashti, O.A. Ogunbiyi, I.J. Kodner, and B.A. Siegel Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer [see comments] Ann Surg 227 1998 319 323
S.K. Libutti, H.R. Alexander Jr, P. Choyke, D.L. Bartlett, S.L. Bacharach, and M. Whatley A prospective study of 2-[18F] fluoro-2-deoxy-D- glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels Ann Surg Oncol 8 2001 779 786
P. Flamen, O.S. Hoekstra, F. Homans, E. Van Cutsem, A. Maes, and S. Stroobants Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) Eur J Cancer 37 2001 862 869
T. Ruers, and R.P. Bleichrodt Treatment of liver metastases, an update on the possibilities and results Eur J Cancer 38 2002 1023 1033
K.N. Boykin, G.B. Zibari, D.L. Lilien, R.W. McMillan, D.F. Aultman, and J.C. McDonald The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver Am Surg 65 1999 1183 1185
R. Hustinx, P. Paulus, N. Jacquet, G. Jerusalem, T. Bury, and P. Rigo Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases Ann Oncol 9 1998 397 401
B. Rydzewski, F. Dehdashti, B.A. Gordon, S.A. Teefey, S.M. Strasberg, and B.A. Siegel Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET AJR Am J Roentgenol 178 2002 353 358
J.V. Vitola, D. Delbeke, M.P. Sandler, M.G. Campbell, T.A. Powers, and J.K. Wright Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver Am J Surg 171 1996 21 26
M. Yang, D.R. Martin, N. Karabulut, and M.P. Frick Comparison of MR and PET imaging for the evaluation of liver metastases J Magn Reson Imaging 17 2003 343 349
H. Zhuang, P. Sinha, M. Pourdehnad, P.S. Duarte, A.J. Yamamoto, and A. Alavi The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver Nucl Med Commun 21 2000 793 798
E.M. Rohren, E.K. Paulson, R. Hagge, T.Z. Wong, J. Killius, and P.A. Clavien The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer Clin Nucl Med 27 2002 550 555
D.T. Lai, M. Fulham, M.S. Stephen, K.M. Chu, M. Solomon, and J.F. Thompson The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver Arch Surg 131 1996 703 707
P. Flamen, S. Stroobants, E. Van Cutsem, P. Dupont, G. Bormans, and N. De Vadder Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer J Clin Oncol 17 1999 894 901
Y. Fong, P.F. Saldinger, T. Akhurst, H. Macapinlac, H. Yeung, and R.D. Finn Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases Am J Surg 178 1999 282 287
T.J. Ruers, B.S. Langenhoff, N. Neeleman, G.J. Jager, S. Strijk, and T. Wobbes Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study J Clin Oncol 20 2002 388 395
D. Delbeke, J.V. Vitola, M.P. Sandler, R.C. Arildsen, T.A. Powers, and J.K. Wright Jr Staging recurrent metastatic colorectal carcinoma with PET J Nucl Med 38 1997 1196 1201
I.A. Zealley, S.J. Skehan, J. Rawlinson, G. Coates, C. Nahmias, and S. Somers Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet Radiographics 21 2001 S55 S69
T.H. Arulampalam, D.L. Francis, D. Visvikis, I. Taylor, and P.J. Ell FDG-PET for the pre-operative evaluation of colorectal liver metastases Eur J Surg Oncol 30 2004 286 291
S.M. Strasberg, F. Dehdashti, B.A. Siegel, J.A. Drebin, and D. Linehan Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study Ann Surg 233 2001 293 299
K.C. Park, J. Schwimmer, J.E. Shepherd, M.E. Phelps, J.R. Czernin, and C. Schiepers Decision analysis for the cost-effective management of recurrent colorectal cancer Ann Surg 233 2001 310 319
J. Meta, M. Seltzer, C. Schiepers, D.H. Silverman, M. Ariannejad, and S.S. Gambhir Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective J Nucl Med 42 2001 586 590
V. Kalff, R.J. Hicks, R.E. Ware, A. Hogg, D. Binns, and A.F. McKenzie The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study J Nucl Med 43 2002 492 499
L. Staib, H. Schirrmeister, S.N. Reske, and H.G. Beger Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180 2000 1 5
T. Arulampalam, D. Costa, D. Visvikis, P. Boulos, I. Taylor, and P. Ell The impact of FDG-PET on the management algorithm for recurrent colorectal cancer Eur J Nucl Med 28 2001 1758 1765
A. Imdahl, M.J. Reinhardt, E.U. Nitzsche, M. Mix, A. Dingeldey, and A. Einert Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences Langenbecks Arch Surg 385 2000 129 134
D.C. Desai, E.E. Zervos, M.W. Arnold, W.E. Burak Jr, J. Mantil, and E.W. Martin Jr Positron emission tomography affects surgical management in recurrent colorectal cancer patients Ann Surg Oncol 10 2003 59 64
M. Simo, F. Lomena, J. Setoain, G. Perez, P. Castellucci, and J.M. Costansa FDG-PET improves the management of patients with suspected recurrence of colorectal cancer Nucl Med Commun 23 2002 975 982
G. Beets, F. Penninckx, C. Schiepers, L. Filez, L. Mortelmans, and R. Kerremans Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer Br J Surg 81 1994 1666 1670
L.G. Strauss, J.H. Clorius, P. Schlag, B. Lehner, B. Kimmig, and R. Engenhart Recurrence of colorectal tumors: PET evaluation Radiology 170 1989 329 332
U. Haberkorn, L.G. Strauss, A. Dimitrakopoulou, R. Engenhart, F. Oberdorfer, and H. Ostertag PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy J Nucl Med 32 1991 1485 1490
H.G. Moore, T. Akhurst, S.M. Larson, B.D. Minsky, M. Mazumdar, and J.G. Guillem A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients J Am Coll Surg 197 2003 22 28
C. Schiepers, K. Haustermans, K. Geboes, L. Filez, G. Bormans, and F. Penninckx The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma Cancer 85 1999 803 811
J.G. Guillem, J. Puig-La Calle Jr, T. Akhurst, S. Tickoo, L. Ruo, and B.D. Minsky Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography Dis Colon Rectum 43 2000 18 24
F.A. Calvo, M. Domper, R. Matute, R. Martinez-Lazaro, J.A. Arranz, and M. Desco 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation Int J Radiat Oncol Biol Phys 58 2004 528 535
M. Findlay, H. Young, D. Cunningham, A. Iveson, B. Cronin, and T. Hickish Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil J Clin Oncol 14 1996 700 708
J.V. Vitola, D. Delbeke, S.G. Meranze, M.J. Mazer, and C.W. Pinson Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization Cancer 78 1996 2216 2222
H. Bender, N. Bangard, N. Metten, M. Bangard, J. Mezger, and A. Schomburg Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer Hybridoma 18 1999 87 91
C.Y. Wong, R. Salem, S. Raman, V.L. Gates, and H.J. Dworkin Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI Eur J Nucl Med Mol Imaging 29 2002 815 820
B.S. Langenhoff, W.J. Oyen, G.J. Jager, S.P. Strijk, T. Wobbes, and F.H. Corstens Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study J Clin Oncol 20 2002 4453 4458
G.S. Anderson, F. Brinkmann, M.C. Soulen, A. Alavi, and H. Zhuang FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation Clin Nucl Med 28 2003 192 197
L.J. Wudel Jr, D. Delbeke, D. Morris, M. Rice, M.K. Washington, and Y. Shyr The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma Am Surg 69 2003 117 124 discussion: 124-6
C. Verhoef, R. Valkema, R.A. de Man, E.P. Krenning, and J.N. Yzermans Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography Liver 22 2002 51 56
J. Trojan, O. Schroeder, J. Raedle, R.P. Baum, G. Herrmann, and V. Jacobi Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma Am J Gastroenterol 94 1999 3314 3319
M.A. Khan, C.S. Combs, E.M. Brunt, V.J. Lowe, M.K. Wolverson, and H. Solomon Positron emission tomography scanning in the evaluation of hepatocellular carcinoma J Hepatol 32 2000 792 797
S.A. Teefey, C.C. Hildeboldt, F. Dehdashti, B.A. Siegel, M.G. Peters, and J.P. Heiken Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET Radiology 226 2003 533 542
S. Liangpunsakul, D. Agarwal, J.C. Horlander, B. Kieff, and N. Chalasani Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation Transplant Proc 35 2003 2995 2997
S. Shiomi, S. Nishiguchi, H. Ishizu, Y. Iwata, N. Sasaki, and A. Tamori Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma Am J Gastroenterol 96 2001 1877 1880
Y. Iwata, S. Shiomi, N. Sasaki, H. Jomura, S. Nishiguchi, and S. Seki Clinical usefulness of positron emission tomography with fluorine-18- fluorodeoxyglucose in the diagnosis of liver tumors Ann Nucl Med 14 2000 121 126
A. Kurtaran, A. Becherer, F. Pfeffel, C. Muller, T. Traub, and J. Schmaljohann 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver Liver 20 2000 487 490
P.C. de Groen, G.J. Gores, N.F. LaRusso, L.L. Gunderson, and D.M. Nagorney Biliary tract cancers N Engl J Med 341 1999 1368 1378
C.D. Anderson, M.H. Rice, C.W. Pinson, W.C. Chapman, R.S. Chari, and D. Delbeke Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma J Gastrointest Surg 8 2004 90 97
R. Kluge, F. Schmidt, K. Caca, H. Barthel, S. Hesse, and P. Georgi Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer Hepatology 33 2001 1029 1035
A. Fritscher-Ravens, K.H. Bohuslavizki, D.C. Broering, L. Jenicke, H. Schafer, and R. Buchert FDG PET in the diagnosis of hilar cholangiocarcinoma Nucl Med Commun 22 2001 1277 1285
Y.J. Kim, M. Yun, W.J. Lee, K.S. Kim, and J.D. Lee Usefulness of (18)F-FDG PET in intrahepatic cholangiocarcinoma Eur J Nucl Med Mol Imaging 30 2003 1467 1472
S. Keiding, S.B. Hansen, H.H. Rasmussen, A. Gee, A. Kruse, and K. Roelsgaard Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography Hepatology 28 1998 700 706
K.L. Berger, S.A. Nicholson, F. Dehdashti, and B.A. Siegel FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features AJR Am J Roentgenol 174 2000 1005 1008
R. Hustinx, R.J. Dolin, F. Benard, A. Bhatnagar, D. Chakraborty, and R.J. Smith Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis Eur J Nucl Med 27 2000 1365 1371
C. Cohade, M. Osman, J. Leal, and R.L. Wahl Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma J Nucl Med 44 2003 1797 1803
R.L. Wahl Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT J Nucl Med 45 Suppl 1 2004 82S 95S
D.L. Francis, A. Freeman, D. Visvikis, D.C. Costa, S.K. Luthra, and M. Novelli In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography Gut 52 2003 1602 1606
D.L. Francis, D. Visvikis, D.C. Costa, T.H. Arulampalam, C. Townsend, and S.K. Luthra Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer Eur J Nucl Med Mol Imaging 30 2003 988 994
D.L. Francis, D. Visvikis, D.C. Costa, I. Croasdale, T.H. Arulampalam, and S.K. Luthra Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both (18)FDG and (18)FLT PET Eur J Nucl Med Mol Imaging 31 2004 928
